open access

Vol 13, No 4 (2009)
Prace oryginalne
Published online: 2009-07-21
Get Citation

The assessment of plasma visfatin concentration in patients with metabolic syndrome and essential hypertension

Joanna Foremska-Iciek, Karolina Hoffmann, Danuta Pupek-Musialik
Nadciśnienie tętnicze 2009;13(4):258-265.

open access

Vol 13, No 4 (2009)
Prace oryginalne
Published online: 2009-07-21

Abstract

Background Visfatin is recently discovered adipocytokine preferentially secreted by visceral adipose tissue. The aims of the study were: estimation of plasma visfatin levels in patients with metabolic syndrome and essential hypertension, assessment of correlations between visfatin and blood pressure values, selected anthropometric and biochemical parameters.
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.

Abstract

Background Visfatin is recently discovered adipocytokine preferentially secreted by visceral adipose tissue. The aims of the study were: estimation of plasma visfatin levels in patients with metabolic syndrome and essential hypertension, assessment of correlations between visfatin and blood pressure values, selected anthropometric and biochemical parameters.
Material and methods Sixty eight patients were qualified for the study and divided into: group 1 - with metabolic syndrome and hypertension (n = 31), group 2 - with essential hypertension (n = 22), group 3 - control group (n = 15). In all subjects we measured: anthropometric measurements, blood pressure values, fat tissue mass, lipid and glycemic profile. Oral glucose tolerance test (OGTT) and insulin-resistance ratio were estimated. Fasting and postprandial visfatin was measured using ELISA method.
Results Mean plasma fasting visfatin in 3 groups was respectively: group 1 - 1.58 ± 1.88 ng/ml, group 2 - 0.82 ± 0.87 ng/ml, group 3 - 1.69 ± 1.58 ng/ml. Mean postprandial plasma visfatin levels in studied groups was respectively: group 1 - 1.36 ± 1.35 ng/ml, group 2 - 0.63 ± 0.44 ng/ml, group 3 - 0.70 ± 0.32 ng/ml. Significant differences were found in group 1 v. 2 and 3. Fasting plasma visfatin correlated with waist circumference and mean diastolic blood pressure value. No significant linear correlation were found between fasting plasma visfatin and insulin-resistance ratio (IRI/G), fat tissue mass, body mass index, triglicerides, HDL cholesterol and OB. No linear relationship was found between plasma visfatin and glucose level.
Conclusions Visfatin may have impact on modulation of hypertension values. There is no relationship between serum visfatin level, insulin- resistance ratio and fat tissue mass despite positive correlation with waist circumference therefore visfatin can not be indicated as a link between obesity and insulin-resistance or as a predictive factor for diabetes type 2 development.
Get Citation

Keywords

visfatin; metabolic syndrome; hypertension; visceral fat tissue

About this article
Title

The assessment of plasma visfatin concentration in patients with metabolic syndrome and essential hypertension

Journal

Arterial Hypertension

Issue

Vol 13, No 4 (2009)

Pages

258-265

Published online

2009-07-21

Bibliographic record

Nadciśnienie tętnicze 2009;13(4):258-265.

Keywords

visfatin
metabolic syndrome
hypertension
visceral fat tissue

Authors

Joanna Foremska-Iciek
Karolina Hoffmann
Danuta Pupek-Musialik

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl